TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy With Pitavastatin in Coronary Artery Disease (REAL-CAD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who met following all criteria are entered in run-in period, loading pitavastatin 1 mg/day for more than 1 month when informed consent was given. (Primary registration)~* Coronary artery disease patients meeting one of the following events~  * History of Acute Coronary Syndrome (AMI or Unstable angina)~ * History of revascularization (PCI or CABG)~ * Diagnosis of ischemic heart disease and coronary artery stenosis as having 75% or higher stenosis according to the AHA classification~* Hypercholesterolemia patients meeting one of following criteria~  * LDL-C is 140 mg/dL or over~ * LDL-C is 100 mg/dL or over and requiring cholesterol lowering drugs judged by attending physicians~ * Patents receiving cholesterol lowering drugs~* Age (≧20 \<80 year-old)~* Patients given written informed consent.~Exclusion Criteria:~Exclusion Criteria(Pre-Run-in period)~* Patients planning revascularization~* Malignant tumor in active phase~* Patients who meet contraindication of LIVALO tablet below~  * Patients who have hypersensitivity to LIVALO tablet~ * Patients who have severe liver dysfunction or biliary atresia~ * Patients who are being treated with cyclosporine~ * Pregnant women, women suspected of being pregnant, or lactating women~* Patients who have heart failure NYHA III or greater~* Patients undergoing dialysis~* Patients with familial hypercholesterolemia~* Patients registered in the other clinical trials~* Patients taking prohibited drugs~* Patients who are ineligible in the opinion of the investigator~Exclusion Criteria(Post-Run-in period)~* LDL-C is 120mg/dL or over after Run-in period~* Patients with occurrence of acute coronary syndrome (AMI or Unstable angina) within 3 months~* Patients who have been undergone PCI or CABG within 3 months~* Compliance is less than 50% in Run-in period~* Patients who met primary endpoint in Run-in period.~* Patients who met adverse events in Run-in period and judged as ineligible in the opinion of the investigator~* Patients who are ineligible in the opinion of the investigator

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Pitavastatin 1 mg daily (Type: ACTIVE_COMPARATOR): None
- Pitavastatin 4 mg daily (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Breastfeeding and Oral Contraceptives: a Randomized, Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* able to give informed consent~* postpartum women delivering at the University of New Mexico Hospital~* Intend to breastfeed~* Plan to use oral contraceptives as her family planning method~* Willing to be randomized to either progestin-only pills or combined pills~Exclusion Criteria:~* medical contraindications to combined pills including history of thromboembolism, uncontrolled hypertension or complex migraine headaches~* preterm birth (\<37 weeks)~* small for gestational age infant (\<2500 grams)~* large for gestational age infant (\>4500 grams)~* infant with major congenital anomaly

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Study Arm A (Type: ACTIVE_COMPARATOR): Study Arm A is one of two interventions (Combined estrogen-progestin pill)
- Study Arm B (Type: ACTIVE_COMPARATOR): Study Arm B is one of two interventions (Progestin-only pill)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CGRP's Cluster Headache Inducing Abilities in Cluster Headache Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fulfillment of IHS criteria for cluster headache either chronic or episodic~* Patients in bouts 1-32 attacks per week~* Patients in remission minimum of 1 month remission time~* fertile women must use safe contraception~Exclusion Criteria:~* All other primary types of headache~* headache 8 hours or less before study day begins~* pregnant or lactating women~* any history or clinical sigs of hyper/hypotension, heart disease, mental disorder, substance abuse, or other illness deemed relevant by the medical doctor assessing the patient

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Active (Type: ACTIVE_COMPARATOR): 1.5µg/min IV calcitonin-gene related peptide for 20 minutes
- Placebo (Type: PLACEBO_COMPARATOR): IV placebo for 20 minutes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female aged 18-65 years old~* Functional Bowel Disorder Severity Index Score above 37~* Normal complete blood count, liver function studies and renal function studies~* Serologies done to rule out Celiac Spure or patient has prior negative EGD with small bowel biopsies which have been negative~* Infectious diarrhea ruled out by stool studies~* Negative colonoscopy~Exclusion Criteria:~* Any history of chronic liver disease, heart disease, pulmonary or renal disease~* Abnormal EKG~* Women with positive pregnancy tests~* Patient on steroids, antacids, or warfarin or chronic pain conditions other than fibromyalgia~* Patients who drink over 2oz alcohol/day on a regular basis Any other causes for diarrhea such as IBD, microscopic colitis, celiac disease, history of abdominal obstruction, pancreatitis, ileus, or any gastrointestinal bleeding.~* Patients with active malignancy in the past five years~* Patient with any history of hypersensitivity reactions to salicylate containing medications due to cross-sensitivity with mesalamine or allergy to mesalamine medications in the past~* Any subjects with fibromyalgia will be excluded from the pain testing portion only~* History of Phenylketonuria due to the aspartame contained in Apriso

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Mesalamine (Type: ACTIVE_COMPARATOR): This group received the drug Mesalamine for 12 weeks then a wash out for 3 weeks prior to crossing over to the placebo arm.
- Placebo (Type: PLACEBO_COMPARATOR): This group will receive the Placebo for 12 weeks then a wash out for 3 weeks prior to crossing over to the drug arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study in Patients With Crohn's Disease Who Are Steroid Dependent, Despite Previous Unsuccessful Attempts to Reduce Steroids Due to Worsening of Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* You must have active Crohn's disease at screening and been diagnosed with Crohn's disease within 6 months at screening.~* You must have steroid dependent disease (receiving between 10-40 mgs/day prednisone therapy for greater than 3 months prior to screening and had at least one unsuccessful attempt to reduce cortico-steroids due to worsening of disease).~* You must be able to give yourself an injection of study drug or have another person help you give the injection.~* You must not be pregnant and agree to use birth control if you are a sexually active male or female of childbearing potential.~Exclusion Criteria:~* You may not be taking medications not allowed on this study.~* You may not have had GI surgery or bowel obstruction in the last 6 months.~* You may not have ever taken this drug or drugs of similar type in the past.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None
- Arm 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Colorectal adenocarcinoma, Wild KRAS, 18-75 yr~* Estimated life expectancy of more than 3 months~* ECOG performance status of 0 to 1 at study entry~* Adequate bone marrow function~* Adequate liver function~* Documented progression during or within 3 months of irinotecan-containing regimens as a first-line chemotherapy~* Immunohistochemical evidence of a presence or absence of EGFR expression by PharmDx Kit~* Informed Consent~Exclusion Criteria:~* Central nervous system (CNS) metastases or prior radiation for CNS metastases.~* Intestinal obstruction or impending intestinal obstruction due to peritoneal carcinomatosis~* Surgery (excluding biopsy for diagnosis) during 4 weeks prior to inclusion in the study.~* Evidence of gastrointestinal bleeding~* Exposure to Cetuximab~* Prior administration of monoclonal antibodies, EGFR signal transduction inhibitors or EGFR-targeted treatment~* KRAS mutant Status~* Patients with serious toxicity to previous irinotecan-based chemotherapy~* Other serious illness or medical conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- EGFR expression (Type: EXPERIMENTAL): Patients' accrual will be adjusted by EGFR expression (positive vs. negative)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Orthodontic Patient Experience of Intraoral Scans Versus Alginate Impressions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* New patients, aged 10 years and old, attending the Royal Derby Hospital orthodontic department, requiring study model impressions taken prior to commencing orthodontic treatment~* Participants must be capable of giving informed consent, or have an acceptable individual capable of giving consent on the patient's behalf (e.g. parent or guardian of a child under 16 years of age).~Exclusion Criteria:~* Patients who have had previous experience of impressions/intraoral scans in the last 2 years~* Cleft lip and/or palate patients~* Patient who have been involved in a study in the last 6 months or are currently part of a study

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Arm 1 - Alginate impressions followed by digital intraoral scan (Type: EXPERIMENTAL): The participant will have alginate impressions taken for orthodontic treatment records first. Followed by a digital intraoral scan a minimum of 4-6 weeks washout period. After each intervention, the participant will complete a modified visual analogue scale (VAS) questionnaire about their experience.
- Arm 2 - Digital intraoral scan followed by alginate impressions (Type: EXPERIMENTAL): The participant will have a digital intraoral taken for orthodontic treatment records first. Followed by alginate impressions a minimum of 4-6 weeks washout period. After each intervention, the participant will complete a modified visual analogue scale (VAS) questionnaire about their experience.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Infants In China

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 42 to 77 days (approximately 2 months) at the time of enrollment.~2. Healthy infant as determined by medical history, physical examination, and judgment of the investigator.~Exclusion Criteria:~1. Previous vaccination with licensed or investigational pneumococcal vaccine.~2. A previous anaphylactic reaction to any vaccine or vaccine-related component.~3. Contraindication to vaccination with pneumococcal vaccines.

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 77 Days
- Healthy Volunteers: t

Study Arms:
- 7vPnC (3-, 4-, 5-, 12-Month) (Type: ACTIVE_COMPARATOR): None
- 13vPnC (3-, 4-, 5-, 12-Month) (Type: EXPERIMENTAL): None
- 13vPnC (2-, 4-, 6-, 12-Month) (Type: EXPERIMENTAL): None
- 13vPnC (3-, 5-, 12-Month) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety And Efficacy Of Rifabutin In Patients For Non-HIV Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients need to be administered Mycobutin® in order to be enrolled in the surveillance.~Exclusion Criteria:~* Patients not administered Mycobutin®.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rifabutin (Type: None): Patients administered Rifabutin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity Study of Aleph Inactivated Split Influenza Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* more than three years in good healthy~Exclusion Criteria:~* current infectious fever or acute disease~* upper respiratory infectious symptom within 6m~* a history of allergy~* laboratory confirmed influenza~* autoimmune disease~* have get influenza vaccine since 2008

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- recombinant hepatitis b vaccine (Type: PLACEBO_COMPARATOR): 0.5ml intramuscular
- Aleph influenza vaccine (Type: EXPERIMENTAL): 0.5ml intramuscular

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Double-blind, Placebo-controlled Study of the Safety and Efficacy of Paliperidone Extended Release (ER) in the Treatment of Schizophrenia in Adolescent Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Must meet the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM IV) criteria for schizophrenia (295.10, 295.20, 295.30, 295.60, 295.90) for 1 year (the diagnosis will be established using the K-SADS-PL, including all supplements)~* Must not be a danger to themselves or others, and must have family support available to be maintained as an outpatient~* Should have had at least 1 adequate treatment with an antipsychotic before participation in this study~* Must have a PANSS score between 60 and 120, inclusive, at screening and baseline~* Weight \>=29 kg~Exclusion Criteria:~* Meet the DSM-IV criteria at screening for dissociative disorder, bipolar disorder, major depressive disorder, schizoaffective disorder, schizophreniform disorder, autistic disorder, or primary substance induced psychotic disorder. Other comorbid disorders e.g., attention-deficit hyperactivity disorder (ADHD) are allowed as long as the diagnosis of schizophrenia is the primary diagnosis and the comorbid disorders in the investigator's judgment do not require medication~* Mild, moderate, or severe mental retardation (i.e., documented intelligence quotient \[IQ\] \<70) established by previous IQ testing or history~* Women who are pregnant (as confirmed by urine pregnancy test performed at screening or baseline), planning to become pregnant or are nursing~* Have a known or suspected history of seizure disorder, or neuroleptic malignant syndrome, encephalopathic syndrome, tardive dyskinesia, or insulin dependent diabetes mellitus~* Presence of any significant or unstable cardiovascular, respiratory, renal, hepatic, hematologic, endocrine, immunologic, or other systemic disease

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): Paliperidone ER 1.5 mg tablet once daily for 6 weeks
- 002 (Type: EXPERIMENTAL): Paliperidone ER 3 mg or 6 mg tablet once daily for 6 weeks
- 003 (Type: EXPERIMENTAL): Paliperidone ER 6 mg or 12 mg tablet once daily for 6 weeks
- 004 (Type: PLACEBO_COMPARATOR): Placebo Once daily for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female subjects, ≥18 to ≤80 years at time of study~2. Status post PCI with stent implantation requiring antiplatelet therapy~3. Willingness to comply with all study-related procedures~Exclusion Criteria:~1. Pending imminent surgery placing patients at increased risk for bleeding with prasugrel or ticagrelor.~2. History of intracranial hemorrhage, TIA, and stroke~3. Active bleeding~4. Need for long-term anticoagulation (i.e. warfarin, dabigatran, rivaroxaban, apixaban, edoxaban, or lovenox).~5. Current or prior (within the past four weeks) treatment with voraxapar (Zontivity).~6. Severe renal or hepatic impairment~7. Treating physician does not want subject to participate~8. Drug allergy to clopidogrel, prasugrel or ticagrelor.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- CYP2C19 Genotype guided (Type: EXPERIMENTAL): Prospective CYP2C19 genotyping to decide antiplatelet therapy.
- Control group (Type: NO_INTERVENTION): Antiplatelet therapy will be decided based on usual care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Definitive diagnosis of Crohn's disease confirmed (at least 3 months prior to study entry) either by radiological, endoscopic or histological evidence, affecting the terminal ileum (L1), colon (L2) or ileocolon (L3)\*. \* Vienna Classification (1998)~* Active Crohn's disease (≥ 220 and ≤ 450) scored over the 7 days prior to the first dose of study drug.~* Patients aged 18 years or above at screening.~Exclusion Criteria:~* Crohn's Disease Related~* Fistula abscess present at screening.~* Stricturing type disease with symptoms or signs of non-inflammatory mechanical obstruction or bowel perforation in last 3 months.~* Short bowel syndrome.~* Functional colostomy or ileostomy (note: patients who have had a temporary stoma in the past, which has been reversed, are eligible to enter the study).~* Positive stool laboratory results for enteric pathogens.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete